{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T05:35:03Z","timestamp":1786772103018,"version":"build-2736575974"},"reference-count":28,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T00:00:00Z","timestamp":1784937600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Life"],"abstract":"<jats:p>Vanishing bile duct syndrome (VBDS) is a rare cholestatic liver disease often associated with drug-induced liver injury, yet systematic data on pharmaceutical triggers remain limited. Using WHO VigiBase, we applied Bayesian disproportionality analysis (IC0.25) to identify drug-event associations that may not be readily apparent in clinical trials or pre-marketing studies. Product labels approved by Swissmedic or the FDA, as well as LiverTox, were reviewed to determine whether VBDS was already acknowledged as an adverse event. Signal detection was deliberately restricted to reports naming a single suspect drug. Among these single-agent reports, 22 drugs demonstrated a positive IC0.25 signal, of which nevirapine, dapsone and azithromycin showed the strongest disproportionality signal. Only one of these agents (carbamazepine) explicitly labelled VBDS as an adverse event. These findings are based on spontaneous reporting data: disproportionality analysis is a hypothesis-generating signal-detection method that does not establish causality and requires further validation. This study expands the current understanding of drug-induced VBDS by reinforcing the associations with known drugs and generating pharmacovigilance signals for new potential VBDS triggers across several drug categories.<\/jats:p>","DOI":"10.3390\/life16081232","type":"journal-article","created":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T01:26:23Z","timestamp":1785115583000},"page":"1232","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Drug-Associated Vanishing Bile Duct Syndrome: Screening for Potential Pharmaceutical Triggers Using the WHO Pharmacovigilance Database"],"prefix":"10.3390","volume":"16","author":[{"given":"Jo\u00e3o Pereira","family":"Soares","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacology and Toxicology, University Hospital Zurich, 8091 Zurich, Switzerland"},{"name":"Faculty of Medicine, University of Zurich, 8006 Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9263-948X","authenticated-orcid":false,"given":"Andreas E.","family":"Kremer","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Zurich, 8006 Zurich, Switzerland"},{"name":"Department of Gastroenterology and Hepatology, University Hospital Zurich, 8091 Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0195-0115","authenticated-orcid":false,"given":"J\u00e9r\u00f4me","family":"Bonzon","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology and Toxicology, University Hospital Zurich, 8091 Zurich, Switzerland"},{"name":"Faculty of Medicine, University of Zurich, 8006 Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Izzo, P., Gallo, G., Pisanelli, M.C., D\u2019onghia, G., Macci, L., Gabriele, R., Polistena, A., Izzo, L., Izzo, S., and Basso, L. (2022). Vanishing bile duct syndrome in an adult patient: Case report and review of the literature. J. Clin. Med., 11.","DOI":"10.3390\/jcm11123253"},{"key":"ref_2","unstructured":"NIDDK (2024, December 06). Vanishing bile duct syndrome, LiverTox: Clinical and Research Information on Drug-Induced Liver Injury, Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK548715\/."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/j.bbadis.2017.08.033","article-title":"Drug-induced bile duct injury","volume":"1864","author":"Visentin","year":"2018","journal-title":"Biochim. Biophys. Acta (BBA)\u2014Mol. Basis Dis."},{"key":"ref_4","first-page":"1232","article-title":"Drug and toxin-induced bile duct disorders","volume":"15","author":"Geubel","year":"2000","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s005340170002","article-title":"Pathology and pathogenesis of intrahepatic bile duct loss","volume":"8","author":"Nakanuma","year":"2001","journal-title":"J. Hepato-Biliary-Pancreat. Surg."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.cld.2007.11.007","article-title":"Vanishing bile duct syndrome","volume":"12","author":"Reau","year":"2008","journal-title":"Clin. Liver Dis."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1007\/s15010-023-02132-6","article-title":"Antibiotic-associated vanishing bile duct syndrome: A real-world retrospective and pharmacovigilance database analysis","volume":"52","author":"Wang","year":"2024","journal-title":"Infection"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1080\/14740338.2024.2416537","article-title":"Nonsteroidal anti-inflammatory drugs-associated vanishing bile duct syndrome: A real-world retrospective and disproportionality analysis","volume":"25","author":"Wang","year":"2024","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Karkra, R., Goyal, R.M., Mohsen, M., Hajifathalian, K., and Al-Khazraji, A. (2026). Drug-induced vanishing bile duct syndrome: A real-world pharmacovigilance study using the FDA Adverse Event Reporting System. Indian J. Gastroenterol.","DOI":"10.1007\/s12664-025-01961-7"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Wei, S., Zhang, Z., Song, X., Chen, R., Chen, S., and Lu, B. (2026). Biliary disorders associated with immune checkpoint inhibitors: A pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database. J. Chemother.","DOI":"10.1080\/1120009X.2025.2612386"},{"key":"ref_11","unstructured":"Uppsala Monitoring Centre (2026, January 09). VigiBase: WHO\u2019s Global Database Signalling Harm and Pointing to Safer Use. Published 5 May 2024. Available online: https:\/\/who-umc.org\/vigibase\/vigibase-who-s-global-database\/."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s13613-022-01026-4","article-title":"Drug-associated hyperammonaemia: A Bayesian analysis of the WHO pharmacovigilance database","volume":"12","author":"Balcerac","year":"2022","journal-title":"Ann. Intensiv. Care"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1177\/009286150804200501","article-title":"VigiBase, the WHO Global ICSR database system: Basic facts","volume":"42","author":"Lindquist","year":"2008","journal-title":"Drug Inf. J."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s002280050466","article-title":"A Bayesian neural network method for adverse drug reaction signal generation","volume":"54","author":"Bate","year":"1998","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/pds.668","article-title":"A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions","volume":"11","author":"Bate","year":"2002","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"ref_16","unstructured":"Panel on Antiretroviral Guidelines for Adults and Adolescents (2026, January 09). Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV, Available online: https:\/\/clinicalinfo.hiv.gov\/en\/guidelines\/hiv-clinical-guidelines-adult-and-adolescent-arv\/whats-new."},{"key":"ref_17","unstructured":"World Health Organization (2018). Guidelines for the Diagnosis, Treatment and Prevention of Leprosy, World Health Organization. Available online: https:\/\/www.who.int\/publications\/i\/item\/9789290226383."},{"key":"ref_18","unstructured":"Panel on Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV (2026, January 09). Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV, Available online: https:\/\/clinicalinfo.hiv.gov\/en\/guidelines\/adult-and-adolescent-opportunistic-infection."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"385","DOI":"10.2165\/00002018-200629050-00003","article-title":"Under-Reporting of Adverse Drug Reactions","volume":"29","author":"Hazell","year":"2006","journal-title":"Drug Saf."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1097\/MOG.0000000000000813","article-title":"Drug-induced bile duct injury: New agents, new mechanisms","volume":"38","author":"Scoazec","year":"2021","journal-title":"Curr. Opin. Gastroenterol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e858","DOI":"10.1097\/MEG.0000000000002280","article-title":"Immune-related cholangitis induced by immune checkpoint inhibitors: A systematic review of clinical features and management","volume":"33","author":"Pi","year":"2021","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1038\/ncponc0555","article-title":"Bortezomib: Efficacy comparisons in solid tumors and hematologic malignancies","volume":"3","author":"Caravita","year":"2006","journal-title":"Nat. Clin. Pract. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"4685","DOI":"10.1158\/1078-0432.CCR-21-0327","article-title":"FDA Approval Summary: Pembrolizumab for the Treatment of Tumor Mutational Burden\u2013High Solid Tumors","volume":"27","author":"Marcus","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_24","unstructured":"(2024, December 06). FDA Label Search. Silver Spring (MD): U.S. Food and Drug Administration, Available online: https:\/\/labels.fda.gov."},{"key":"ref_25","unstructured":"(2024, December 06). AIPS (Arzneimittel-Informations-Publikationssystem) Swissmedic. Available online: https:\/\/www.swissmedicinfo.ch."},{"key":"ref_26","unstructured":"Council for International Organizations of Medical Sciences (2020). Drug-Induced Liver Injury (DILI): Current Status and Future Directions for Drug Development and the Post-Market Setting. A Consensus by a CIOMS Working Group, CIOMS."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/hep.510260319","article-title":"Development and validation of a clinical scale for the diagnosis of drug-induced hepatitis","volume":"26","author":"Maria","year":"1997","journal-title":"Hepatology"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1002\/cpt.3701","article-title":"FDA Adverse Event Reporting System (FAERS) Essentials: A Guide to Understanding, Applying, and Interpreting Adverse Event Data Reported to FAERS","volume":"118","author":"Potter","year":"2025","journal-title":"Clin. Pharmacol. Ther."}],"container-title":["Life"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-1729\/16\/8\/1232\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T01:37:06Z","timestamp":1785116226000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-1729\/16\/8\/1232"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,25]]},"references-count":28,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["life16081232"],"URL":"https:\/\/doi.org\/10.3390\/life16081232","relation":{},"ISSN":["2075-1729"],"issn-type":[{"value":"2075-1729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,25]]}}}